Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective Pilot Study of Botox-A for Low Anterior Resection Syndrome
2021-000593-29Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of botulinum toxin type A in low anterior resection syndrome (LARS), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Proportion of patients with persistent severe LARS (score > 20) at 3 months after Botox-A injection. Started Mar 2021; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
low anterior resection syndrome (LARS)
Beyond the preview
Go deeper on 2021-000593-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000593-29.